Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County Olysio Coverage Policy | OpenPayer
    Ask Trek AI about this page
    RetiredVentura County Health Care PlanPolicy N/A

    Olysio (simeprevir) Prior Authorization

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization for Olysio in adults with genotype 1 chronic hepatitis C, including certain post-liver-transplant cases and completion of an approved treatment course.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyOlysio (simeprevir) Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material changearchived
    Effective DateJul 24, 2018
    Last ReviewJan 22, 2019
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with the patient's age, HCV genotype, fibrosis score, cirrhosis status when applicable, Q80K status, treatment regimen, transplant history, and prescribing specialist documented.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 weeksStandard treatment duration
    24 weeksMaximum treatment duration
    ≥18 yearsMinimum patient age
    ≥2Minimum fibrosis score
    Archived

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy status

    Coverage Criteria

    FDA-Approved Chronic HCV Genotype 1

    Covered for FDA-approved chronic hepatitis C virus (HCV) genotype 1 when ALL of the following criteria are met:

    ALL of the following

    • The patient is ≥ 18 years of age.
    • Olysio is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician.
    • For patients with genotype 1a, the patient does not have the Q80K polymorphism. Testing for the Q80K polymorphism is not required for patients with genotype 1b.
    • The patient has a fibrosis score of ≥ 2.
    • ONE of the following duration criteria is met:

      • Olysio will be prescribed in combination with Sovaldi, and the patient does not have cirrhosis.12 weeks
      • Olysio will be prescribed in combination with Sovaldi, and the patient has cirrhosis.24 weeks

    Recurrent HCV After Liver Transplantation, Genotype 1

    Covered for recurrent HCV after liver transplantation when ALL of the following criteria are met. AASLD guidelines identify Sovaldi plus Olysio, with or without weight-based ribavirin, for 12 weeks as an alternative regimen for genotype 1 recurrent HCV post-liver transplantation with compensated disease (Class I, Level B).

    ALL of the following

    • The patient is ≥ 18 years of age.
    • The patient has genotype 1 recurrent hepatitis C virus (HCV) after a liver transplantation.
    • Olysio is prescribed by or in consultation with one of the following prescribers: a prescriber affiliated with a liver transplant center, a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician.
    • If the patient has genotype 1a, the patient does not have the Q80K polymorphism. Testing for the Q80K polymorphism is not required for patients with genotype 1b.

    Continuation Therapy

    Continuation therapy is covered to complete a course of therapy that has already been approved under an FDA-approved indication or other use with supportive evidence.

    ALL of the following

    • The patient has been started on Olysio for an indication or condition addressed as an approval in the FDA-approved indications or other use with supportive evidence criteria.
    • Authorization for Olysio does not exceed 24 weeks of total therapy.
    • The requested duration is limited to the remaining portion of the approved treatment course.

      For example, if the patient is eligible for 12 weeks of therapy and has received 3 weeks, approve 9 additional weeks to complete the 12-week course.

    Olysio is not approved for the following uses: life expectancy of less than 12 months due to non-liver-related comorbidities; monotherapy with Olysio; pediatric patients younger than 18 years of age; or patients who have failed therapy with Olysio or another NS3/4A protease inhibitor for hepatitis C virus (HCV), including Incivek (telaprevir tablets) or Victrelis (boceprevir capsules). Failure includes prior null response, partial response, or relapse. This exclusion does not include patients who discontinued Incivek or Victrelis because of an adverse reaction to those medications.

    Clinical Coding Requirements

    Fibrosis Score
    Required fibrosis score≥ 2
    Applicable populationAdults with chronic HCV genotype 1
    Treatment requirementMust be met along with the other coverage criteria

    Authorization and Documentation

    Prior Authorization

    Genotype 1 Prior Authorization Required

    Prior authorization is required for Olysio in adults with chronic HCV genotype 1. The request must document the qualifying prescriber, genotype-specific Q80K status, fibrosis score, treatment combination, and cirrhosis status.

    • Patient is 18 years or older.
    • Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician.
    • For genotype 1a, the patient must not have the Q80K polymorphism; Q80K testing is not required for genotype 1b.
    • Fibrosis score is ≥ 2.
    • Olysio is prescribed in combination with Sovaldi: approve 12 weeks without cirrhosis or 24 weeks with cirrhosis.
    Prior Authorization

    Post-Transplant Authorization

    Authorize Olysio for 12 weeks for recurrent genotype 1 HCV after liver transplantation only when all post-transplant criteria are documented.

    Medication and Policy Background

    Olysio (simeprevir) is an HCV NS3/4A protease inhibitor used as part of combination antiviral therapy for chronic hepatitis C. This policy addresses coverage and prior authorization for adults with genotype 1 HCV, including recurrent genotype 1 HCV after liver transplantation. For the specified regimens, Olysio is used with Sovaldi, and treatment duration depends on cirrhosis status: 12 weeks for noncirrhotic disease and 24 weeks for cirrhotic disease; recurrent post-transplant HCV is treated for 12 weeks.

    Initial Therapy Criteria

    Initial Therapy for Chronic Genotype 1 HCV

    Approve for the specified duration when all criteria are met.

    FDA-approved genotype 1 HCV treatment

    • Age: Patient is at least 18 years old.≥ 18 years
    • Specialist involvement: Olysio is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician.
    • Genotype 1a Q80K status: For genotype 1a, the patient does not have the Q80K polymorphism; Q80K testing is not required for genotype 1b.

    Continuation Therapy

    Completion of Started Therapy

    Patients who have started Olysio may be approved to complete a course that meets an approved indication.

    Complete approved course

    • Approved indication: The patient is being treated for an FDA-approved indication or other supportive-evidence indication addressed by this policy.
    • Remaining duration: Requested authorization covers only the remaining weeks of the approved course, and total Olysio therapy does not exceed 24 weeks.≤ 24 weeks total

    Authorization Duration Limits

    Noncirrhotic Genotype 1 HCV
    Treatment duration12 weeks per course
    RegimenOlysio in combination with Sovaldi
    Cirrhosis statusPatient does not have cirrhosis
    Cirrhotic Genotype 1 HCV
    Maximum treatment duration24 weeks per course
    RegimenOlysio in combination with Sovaldi
    Cirrhosis statusPatient has cirrhosis
    Policy Summary
    PayerVentura County Health Care Plan
    PolicyOlysio (simeprevir) Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material changearchived
    Effective DateJul 24, 2018
    Last ReviewJan 22, 2019
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with the patient's age, HCV genotype, fibrosis score, cirrhosis status when applicable, Q80K status, treatment regimen, transplant history, and prescribing specialist documented.
    SourceLink
    On This Page
    Coverage CriteriaClinical Coding RequirementsAuthorization and DocumentationMedication and Policy BackgroundInitial Therapy CriteriaContinuation TherapyAuthorization Duration Limits
    Olysio is prescribed in combination with Sovaldi.12 weeks
  1. Patient is 18 years or older and has recurrent genotype 1 HCV after liver transplantation.
  2. Prescriber is affiliated with a liver transplant center or is a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician.
  3. For genotype 1a, the patient must not have the Q80K polymorphism; testing is not required for genotype 1b.
  4. Olysio must be prescribed in combination with Sovaldi.
  5. AASLD-supported regimen: Sovaldi plus Olysio, with or without weight-based ribavirin, for 12 weeks in compensated recurrent disease.
  6. Billing Rule

    Continuation of an Existing Course

    Patients already taking Olysio may receive authorization to complete an approved course for an eligible indication or supportive-evidence use. Total Olysio authorization must not exceed 24 weeks.

    • Authorize only the remaining time in the approved course.
    • Example: a patient eligible for 12 weeks who has completed 3 weeks may receive authorization for 9 additional weeks.
    • The maximum total authorization duration is 24 weeks.
    Documentation Required

    Clinical Eligibility Documentation

    The authorization request must include clinical documentation supporting the applicable indication and treatment duration. Use the following elements to establish eligibility and determine the requested course.

    • Age and HCV genotype, including recurrent infection after liver transplantation when applicable.
    • Prescriber specialty and, for post-transplant cases, affiliation with a liver transplant center when applicable.
    • Q80K polymorphism result for genotype 1a; testing is not required for genotype 1b.
    • Fibrosis score and cirrhosis status for chronic genotype 1 treatment.
    • Current or planned concomitant therapy with Sovaldi.
    • For continuation requests, the approved indication, total planned course, and number of weeks already received.
    Denial Risk

    Noncovered Uses and Prior Protease Inhibitor Failure

    Olysio is not approved for the uses and treatment histories listed below. Requests involving these circumstances should be denied unless the policy specifically excludes only the documented adverse-reaction exception.

    • Life expectancy of less than 12 months due to non-liver-related comorbidities.
    • Olysio monotherapy.
    • Pediatric patients younger than 18 years.
    • Prior failure of Olysio or another HCV NS3/4A protease inhibitor, including Incivek (telaprevir) or Victrelis (boceprevir).
    • Discontinuation of Incivek or Victrelis because of an adverse reaction is not considered treatment failure.
    Denial Risk

    Failure to Meet Clinical Criteria

    Failure to satisfy any required clinical criterion creates a denial risk. The request must establish the approved indication, appropriate treatment and prescriber, genotype-specific eligibility, and all applicable disease-severity and transplant requirements.

    • Deny when the patient is younger than 18 years.
    • Deny when Olysio is prescribed without Sovaldi or by a prescriber who does not meet the specialty or consultation requirements.
    • Deny genotype 1a treatment when Q80K polymorphism is present or when required genotype information is missing; Q80K testing is not required for genotype 1b.
    • Deny chronic genotype 1 requests when fibrosis is 2 or cirrhosis status does not support the requested 12- or 24-week duration.
    • Deny post-transplant requests without recurrent genotype 1 HCV after liver transplantation, required transplant-center or specialist involvement, or the required Sovaldi combination.
    • Deny continuation requests that exceed the approved course or the 24-week maximum total authorization.
    Fibrosis: Patient has a fibrosis score of at least 2.≥ 2
  7. ONE of the following treatment-duration pathways

    • Noncirrhotic treatment: Olysio is prescribed in combination with Sovaldi and the patient does not have cirrhosis.12 weeks

      Approve for 12 weeks.

    • Cirrhotic treatment: Olysio is prescribed in combination with Sovaldi and the patient has cirrhosis.24 weeks

      Approve for 24 weeks.

  8. Initial Therapy After Liver Transplantation

    Approve for 12 weeks when all criteria are met.

    Post-liver-transplant recurrent genotype 1 HCV

    • Age: Patient is at least 18 years old.≥ 18 years
    • Recurrent genotype 1 HCV: Patient has genotype 1 recurrent hepatitis C virus after liver transplantation.
    • Specialist or transplant-center involvement: Olysio is prescribed by or in consultation with a prescriber affiliated with a liver transplant center, a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician.
    • Genotype 1a Q80K status: If the patient has genotype 1a, the patient does not have the Q80K polymorphism; testing is not required for genotype 1b.
    • Combination regimen: Olysio is prescribed in combination with Sovaldi.
    Recurrent HCV After Liver Transplantation
    Treatment duration12 weeks per course
    RegimenOlysio in combination with Sovaldi
    Clinical circumstanceRecurrent genotype 1 HCV after liver transplantation
    Continuation Therapy
    Maximum total authorization24 weeks of therapy
    Continuation amountAuthorize only the remaining duration of the approved course
    ExampleIf 3 weeks of a 12-week course have been received, approve 9 additional weeks